Ribociclib (Kisqali)

Read full text Summarise with VIRAT
Authors: CDA-AMC
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Canada’s Drug Agency (CDA-AMC) recommends that Kisqali in combination with an aromatase inhibitor (AI) should be reimbursed by public drug plans for the adjuvant treatment of adult patients with hormone receptor (HR)–positive, HER2‑negative stage II or III early breast cancer (eBC) at high risk for recurrence, if certain conditions are met. Kisqali, in combination with an AI, should only be covered to treat adults with breast cancer that has receptors for estrogen and progesterone hormones, tests negative for the HER2 protein, has been surgically removed, and has not spread to other parts of the body. It should only be used in patients with stage IIA, IIB, or III disease. For stage IIA node-negative disease, the cancer must also be either grade 3 or grade 2 with high-risk features (e.g., a Ki-67 proliferation index score ≥ 20%), or the patient must have a high-risk result with a genomic test. Eligible patients should also have good performance status. Kisqali, in combination with an AI, should only be reimbursed if prescribed by clinicians with expertise in managing eBC and if the cost of Kisqali is reduced.

Fields of Study & Subjects

Advanced Breast Cancer Therapies Breast Cancer Treatment Studies Health Systems Economic Evaluations Quality of Life

Publication details

Journal / source
Canadian Journal of Health Technologies
Volume
6
Issue
3
Publication date
24 March 2026
Language
EN